Bon Natural Life (BON) AI Stock Analysis

• Market Cap: $11.87M
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: -15.44%
• EPS Growth: -94.04%
• Country: US
• Employees: 97
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Packaged Foods
• EPS (TTM): N/A
• Shares Outstanding: 6,086,971
• 10 Day Avg. Volume: 115,576
• 30 Day Avg. Volume: 2,242,045
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.29
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 0.80
• Enterprise Value/Gross Profit: 3.85
• Enterprise Value/Ebitda: 681.58
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-11.76% Downside)
• Action: Downgraded Date: 01/26/26
• Date: Action: Downgraded 01/26/26

The score is primarily constrained by weak financial performance—especially persistent negative free cash flow and deteriorating profitability. Technical indicators are mixed/neutral with mild bearish momentum, and valuation is challenging due to losses (negative P/E) with no dividend support.

Positive Factors

Balance-sheet strength

Rising equity and low reported leverage provide a durable financial buffer that supports continued R&D, working capital and strategic investments without immediate refinancing. This balance-sheet cushion reduces bankruptcy risk and gives management flexibility to execute long-term growth initiatives.

AI-driven biomanufacturing partnership

The joint lab and multi-year cooperation institutionalize R&D and scale-up capabilities in AI-enhanced bio-manufacturing. Structurally this can lower production costs, improve ingredient quality and supply reliability, strengthening BON's competitive moat in natural active ingredients over coming years.

Contracted sales expansion

A $12M distribution agreement increases contracted revenue and broadens market access in Greater China. This structural commercial partnership supports scale, improves revenue visibility, and can boost manufacturing utilization and bargaining power with suppliers, aiding medium-term margin recovery.

Negative Factors

Persistent negative free cash flow

Sustained negative free cash flow forces reliance on external funding or equity dilution to sustain operations and capex. Over months this constrains strategic flexibility, increases financing costs, and risks underinvestment in manufacturing scale or clinical validation needed for product commercialization.

Declining revenue and margin compression

Falling sales and materially compressed gross margins indicate structural pricing pressure or rising input costs. The swing to a net loss erodes internal funding for growth and weakens operating leverage, making it harder to invest in marketing, R&D and scale required to restore prior profitability levels.

Rising debt and negative ROE

Increased borrowings alongside negative returns on equity heighten financial risk if profitability does not rebound. Higher leverage raises interest and covenant exposure, reducing resilience to further margin pressure and limiting options for opportunistic investments or M&A that could accelerate recovery.

Bon Natural Life Business Overview & Revenue Model

Company Description

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

How the Company Makes Money

Bon Natural Life generates revenue primarily through the sale of its dietary supplements and personal care products. The company utilizes a multi-channel distribution strategy, selling directly to consumers via its online platform as well as through retail partnerships with health food stores and wellness-focused retailers. Key revenue streams include product sales, subscription services for regular customers, and bulk orders from health professionals and wellness practitioners. Additionally, BON may engage in partnerships with other brands and influencers in the wellness space to enhance visibility and reach, further contributing to its earnings.

Bon Natural Life Financial Statement Overview

Summary

Overall fundamentals are weak: the income statement shows falling revenue, margin compression, and a swing to a net loss in 2025, while cash flow is a major red flag with persistently negative free cash flow and very thin/negative operating cash flow. The balance sheet is a relative support with low debt-to-equity and higher equity, but rising debt and negative ROE increase risk if profitability does not recover.

Income Statement

Profitability has deteriorated sharply. Revenue fell to $18.7M in 2025 (down ~14% year over year) after earlier years of stronger sales, and margins compressed meaningfully (gross margin ~21% vs ~30% in 2023–2024). The company swung from a modest profit in 2024 to a net loss of about $2.0M in 2025, with operating results also turning negative—signaling weakening pricing/power and/or higher cost pressure. Strength: the business demonstrated solid profitability in 2020–2023, showing the model can work in better conditions.

Balance Sheet

Leverage appears manageable, with debt-to-equity around 0.21 in 2025 (still relatively low). Equity has grown over time (about $57.6M in 2025 vs $10.5M in 2020), providing a balance-sheet buffer. Weakness: returns on equity flipped negative in 2025 due to the loss, and total debt has risen notably versus prior years (about $12.3M in 2025 vs $7.3M in 2024), which increases risk if profitability does not recover.

Cash Flow

Cash generation is a major concern. Free cash flow is consistently negative across the period and worsened to about -$4.2M in 2025, while cash generated from core operations is extremely thin in 2025 (~$0.14M) and was negative in multiple prior years (notably 2022–2024). The mix of losses (2025) and ongoing cash burn suggests reliance on external funding or balance-sheet liquidity to sustain investment and operations. Strength: the company did generate positive operating cash flow in 2020 and 2021, but this has not been sustained.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	18.67M	23.84M	29.52M	29.91M	25.49M
Gross Profit	3.88M	7.11M	8.84M	9.42M	7.11M
EBITDA	-57.83K	2.30M	6.98M	8.33M	6.13M
Net Income	-1.99M	398.17K	4.60M	6.24M	4.59M
Balance Sheet
Total Assets	85.19M	61.77M	46.56M	37.26M	36.41M
Cash, Cash Equivalents and Short-Term Investments	6.27M	80.47K	111.30K	840.86K	3.61M
Total Debt	12.32M	7.30M	4.21M	5.41M	3.21M
Total Liabilities	27.19M	17.42M	10.57M	7.16M	9.88M
Stockholders Equity	57.55M	43.91M	35.48M	29.56M	26.01M
Cash Flow
Free Cash Flow	-4.23M	-7.73M	-713.82K	-4.92M	-700.78K
Operating Cash Flow	141.12K	-7.72M	-651.91K	-187.12K	4.05M
Investing Cash Flow	-10.00M	-15.73K	-1.19M	-3.06M	-7.44M
Financing Cash Flow	15.45M	8.76M	1.16M	2.26M	5.35M

Bon Natural Life Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BON, the sentiment is Negative. The current price of 1.7 is above the 20-day moving average (MA) of 1.61, above the 50-day MA of 1.64, and above the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 32.16 is Neutral, neither overbought nor oversold. The STOCH value of 26.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BON.

Bon Natural Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
LSF	52 Neutral	$27.30M	-15.26	-14.63%	―	17.73%	-34.71%
BON	46 Neutral	$11.87M	-2.69	1.32%	―	-15.44%	-94.04%
NAII	46 Neutral	$16.99M	-2.11	-15.93%	―	18.19%	-35.22%
HCWC	46 Neutral	$4.84M	-2.13	―	―	―	―
FAMI	42 Neutral	$18.23M	-0.07	-3.22%	―	-49.19%	-394.71%

Bon Natural Life Corporate Events

Bon Natural Life Deepens AI-Driven Biomanufacturing Push With Chang’an Pilot Joint Lab

Bon Natural Life Limited, a Nasdaq-listed supplier of natural active ingredients for health and personal care products, operates globally with a portfolio spanning plant-based extracts, functional food ingredients and personal care actives. The company relies on advanced extraction and biosynthesis technologies, including an AI-driven bio-manufacturing platform, to support large-scale, high-quality production for customers in major markets worldwide.

On January 22, 2026, Bon’s subsidiary Xi’an App-Chem Bio-Tech Co., Ltd. signed a three-year framework cooperation agreement with Shaanxi Chang’an Pilot Life Science Industry Innovation Center to build an integrated innovation chain from basic research to industrial application. Under this collaboration, formally highlighted on February 17, 2026, the parties inaugurated the BON & Pilot Joint Laboratory on December 18, 2025 to develop AI-enhanced biomanufactured natural ingredients, and plan an engineering center plus broader R&D, market and capital partnerships that could bolster Bon’s efficiency, supply reliability and competitive position in bio-manufactured ingredients.

The most recent analyst rating on (BON) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.

Bon Natural Life Secures $12 Million Deal with Qingshengyuan for Kombucha Products

On December 5, 2025, Bon Natural Life Limited announced a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd., marking a significant expansion in the functional health product market in China. This agreement, valued at $12 million over 24 months, allows Qingshengyuan to market and distribute BON’s kombucha-inspired tea pigment products across Greater China. The partnership is expected to enhance BON’s market presence and support the development of its tea-pigment product portfolio, aligning with the increasing consumer interest in natural ingredients and health benefits.

The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.